SABS
SAB Biotherapeutics, Inc.
There isn't enough reported data to score SABS yet.
SABS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SABS's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
SABS PE Valuation
SABS has no meaningful PE right now: it lost money over the past year.
SABS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect SABS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
SABS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.09 | +$3.10 |
| Q2 2025 | -$4.00 | +$2.07 |
| Q1 2025 | -$3.70 | +$2.98 |
| Q4 2024 | -$3.68 | +$3.96 |
| Q3 2024 | -$6.19 | -$0.46 |
| Q2 2024 | -$6.07 | +$0.26 |
| Q1 2024 | -$6.68 | -$0.65 |
| Q4 2023 | -$7.64 | -$3.31 |
SABS is still losing money, but far less than before: $3.09 per share over the past year, against $9.10 at its worst in early 2022.
SABS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $114.7K | -62% |
| Q2 2024 | $263.1K | +208% |
| Q1 2024 | $944.6K | +63% |
| Q4 2023 | $305K | -86% |
| Q3 2023 | $1.3M | -65% |
| Q2 2023 | $85.5K | -99% |
| Q1 2023 | $581.1K | -95% |
| Q4 2022 | $2.2M | -80% |
SABS's revenue has slid since its 2022 peak: $114,698 last quarter, down 62% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -8726% | -2538 points |
| Q2 2024 | -3877% | +3696 points |
| Q1 2024 | -1206% | +68 points |
| Q4 2023 | -6188% | -5824 points |
| Q3 2023 | -420% | -203 points |
| Q2 2023 | -7573% | -7470 points |
| Q1 2023 | -1274% | -1217 points |
| Q4 2022 | -364% | -297 points |
SABS's operating margin was −8726% last quarter, down 8306 points from the same quarter a year ago, near the bottom of its range since 2021.
SABS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$9.6M | +$3.9M |
| Q3 2024 | -$6.4M | -$1.1M |
| Q2 2024 | -$7.8M | -$2.8M |
| Q1 2024 | -$10.9M | -$9.3M |
| Q4 2023 | -$13.5M | -$11.8M |
| Q3 2023 | -$5.3M | +$3M |
| Q2 2023 | -$4.9M | +$900.1K |
| Q1 2023 | -$1.6M | +$10M |
SABS has burned cash in almost every quarter: −$51M over the past year, against −$39M the year before.
SABS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +13.5M shares |
| 1 year | +903% | +83.9M shares |
| 3 years | +1750% | +88.2M shares |
| 5 years | +37195% | +93M shares |
SABS has 93M diluted shares, up 903% from a year ago.
SABS Net Leverage
SABS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SABS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 46.0 | Neutral |
SABS's weekly RSI is 45 (neutral) and its Stochastic is 46 (neutral).
SABS PE vs Healthcare Sector
| Metric | SABS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SABS has no meaningful PE right now: it lost money over the past year.
SABS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.01 | 2.3% above |
| 20 week MA | $3.41 | 9.7% below |
| 50 week MA | $3.66 | 16% below |
| 100 week MA | $3.02 | 2% above |
| 200 week MA | $4.35 | 29% below |
SABS's trend is mixed: it's above two of its five weekly moving averages, and 29% below its 200-week average.
SABS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $102.1 | $87.5 | -14% |
| 2022 | $87.5 | $6.90 | -92% |
| 2023 | $6.90 | $6.88 | -0.3% |
| 2024 | $6.88 | $4.18 | -39% |
| 2025 | $4.18 | $3.78 | -9.6% |
| 2026 YTD | $3.78 | $3.08 | -19% |
SABS has finished every year since 2021 lower, and it's down 19% so far in 2026.